Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Duke Molecular Physiology Institute, Durham, North Carolina.
J Am Coll Cardiol. 2019 Jan 22;73(2):177-186. doi: 10.1016/j.jacc.2018.10.059.
Circulating high-density lipoprotein particle (HDL-P) subfractions impact atherogenesis, inflammation, and endothelial function, all of which are implicated in the pathobiology of heart failure (HF).
The authors sought to identify key differences in plasma HDL-P subfractions between patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) to determine their prognostic utility.
Patients with HFrEF (n = 782), HFpEF (n = 1,004), and no HF (n = 4,742) were identified in the CATHGEN (Catheterization Genetics) biorepository of sequential patients undergoing cardiac catheterization. Nuclear magnetic resonance-based lipoprotein profiling was performed on frozen fasting plasma obtained at catheterization. The authors used multivariable analysis of covariance to compare high-density lipoprotein particle (HDL-P) subfractions across groups, and Cox proportional hazards modeling to determine associations between HDL-P subfractions and time to death or major adverse cardiac events.
Mean HDL-P size was greater in HFrEF than HFpEF, both of which were greater than in no HF (all 2-way p < 0.0001). By contrast, concentrations of small HDL-P and total HDL-P were lesser in HFrEF than HFpEF, which were both lesser than no HF (all 2-way p ≤ 0.0002). In both HFrEF and HFpEF, total HDL-P and small HDL-P were inversely associated with time to adverse events. These findings persisted after adjustment for 14 clinical covariates (including high-density lipoprotein cholesterol content, coronary artery disease, and the inflammatory biomarker GlycA), and in sensitivity analyses featuring alternate left ventricular ejection fraction definitions, or stricter inclusion criteria with diastolic dysfunction or left ventricular end-diastolic pressure thresholds.
In the largest analysis of HDL-P subfractions in HF to date, derangements in HDL-P subfractions were identified that were more severe in HFrEF than HFpEF and were independently associated with adverse outcomes. These data may help refine risk assessment and provide new insights into the complex interaction of HDL and HF pathophysiology.
循环高密度脂蛋白颗粒(HDL-P)亚组分影响动脉粥样硬化、炎症和内皮功能,所有这些都与心力衰竭(HF)的病理生理学有关。
作者试图确定射血分数降低的心力衰竭(HFrEF)和射血分数保留的心力衰竭(HFpEF)患者之间血浆 HDL-P 亚组分的关键差异,以确定其预后效用。
在接受心导管检查的连续患者的 CATHGEN(导管遗传学)生物库中,确定了 HFrEF(n=782)、HFpEF(n=1004)和无 HF(n=4742)患者。在导管检查时获得的空腹冷冻血浆上进行基于核磁共振的脂蛋白谱分析。作者使用协方差的多变量分析比较各组之间的高密度脂蛋白颗粒(HDL-P)亚组分,并使用 Cox 比例风险模型确定 HDL-P 亚组分与死亡或主要不良心脏事件时间之间的关联。
与 HFpEF 相比,HFrEF 的平均 HDL-P 粒径更大,而 HFpEF 又大于无 HF(所有 2 路 p<0.0001)。相比之下,HFrEF 中的小 HDL-P 和总 HDL-P 浓度低于 HFpEF,HFpEF 又低于无 HF(所有 2 路 p≤0.0002)。在 HFrEF 和 HFpEF 中,总 HDL-P 和小 HDL-P 与不良事件时间呈负相关。这些发现在调整 14 个临床协变量(包括高密度脂蛋白胆固醇含量、冠状动脉疾病和炎症生物标志物 GlycA)后仍然存在,并且在使用替代左心室射血分数定义或更严格的纳入标准,包括舒张功能障碍或左心室舒张末期压力阈值的敏感性分析中仍然存在。
在迄今为止最大的 HF 中 HDL-P 亚组分分析中,发现了 HDL-P 亚组分的紊乱,在 HFrEF 中比 HFpEF 更严重,并且与不良结局独立相关。这些数据可能有助于完善风险评估,并为 HDL 和 HF 病理生理学的复杂相互作用提供新的见解。